Trademark: 90592998
Status Date
Monday, February 27, 2023
Filing Date
Monday, March 22, 2021
Published for Opposition
Tuesday, November 30, 2021
Abandoned Date
Monday, February 27, 2023
5 Pharmaceutical products for the treatment of cancer or infectious diseases, namely, genetically engineered hematopoietic cells for the treatment of cancer or infectious diseases; pharmaceutical preparations for cell therapy, namely, genetically engineered hematopoietic cells for the treatment of cancer or infectious diseases; biological preparations for cancer therapies and anti-infective therapies, namely, chimeric antigen receptors (CAR) and therapeutic preparations thereof, namely, viral vectors and plasmid vectors expressing CAR genes; therapeutic antibodies for use as immunotherapeutic agents for the treatment of cancer and infectious diseases; therapeutic T-cell receptors for use as immunotherapeutic agents for the treatment of cancer and infectious diseases; preparations for genetically modifying human or animal cells for medical purposes, including viral vectors and plasmid vectors
44 Medical services, namely, in the extraction of human hematopoietic cells from patients and in genetically modifying hematopoietic cells for therapeutic purposes; Providing medical and therapy advice and consultancy in the field of medical therapies, namely, in the field of genetically engineered hematopoietic cells, cellular therapies, antibody therapies, and T-cell receptor therapies for the treatment of cancer or infectious diseases; providing information regarding the treatment of cancer and infectious diseases by means of a website, namely, in the treatment of cancer and infectious diseases by genetically engineered hematopoietic cells, cellular therapies, antibody therapies, and T-cell receptor therapies
42 Industrial scientific analysis in the field of pharmaceuticals and biotechnology, namely, in the field of genetically engineered hematopoietic cells, cell therapies, chimeric antigen receptors (CAR), therapeutic antibodies, therapeutic T-cell receptors, viral vectors and plasmid vectors; scientific research services in the field of pharmaceuticals and biotechnology, namely, genetically modifying human or animal cells to enable cells to be used for therapeutic purposes; scientific research in the development of cancer therapies or anti-infective therapies, namely, in the development of genetically engineered hematopoietic cells, cell therapies, chimeric antigen receptors (CAR), therapeutic antibodies, therapeutic T-cell receptors and viral vectors and plasmid vectors
Feb 16, 2024
Teas Change Of Correspondence Received
Feb 16, 2024
Attorney/Dom.Rep.Revoked And/Or Appointed
Feb 16, 2024
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Feb 27, 2023
Abandonment Notice E-Mailed - No Use Statement Filed
Feb 27, 2023
Abandonment - No Use Statement Filed
Jun 24, 2022
Notice Of Approval Of Extension Request E-Mailed
Jun 22, 2022
Sou Extension 1 Granted
Jun 22, 2022
Sou Extension 1 Filed
Jun 22, 2022
Sou Teas Extension Received
May 19, 2022
Automatic Update Of Assignment Of Ownership
Jan 25, 2022
Noa E-Mailed - Sou Required From Applicant
Dec 6, 2021
Teas Change Of Correspondence Received
Dec 6, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
Dec 6, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Nov 30, 2021
Official Gazette Publication Confirmation E-Mailed
Nov 30, 2021
Published For Opposition
Nov 10, 2021
Notification Of Notice Of Publication E-Mailed
Oct 26, 2021
Approved For Pub - Principal Register
Oct 26, 2021
Assigned To Examiner
Jun 24, 2021
New Application Office Supplied Data Entered
Mar 25, 2021
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
